今年5月，在与法国制药巨头赛诺菲(SNY.US)达成许可协议后，诺瓦瓦克斯医药解除了此前发布的“持续经营”警告。Novavax (NVAX.US) sold its manufacturing facility in the Czech Republic for $0.2 billion to Novo Nordisk (NVO.US).
According to Zhito Finance APP, Novavax (NVAX.US) sold its manufacturing facility in the Czech Republic for $0.2 billion to Novo Nordisk (NVO.US).
Novavax has been struggling with declining sales of its only marketed product, the COVID vaccine, and warned about its ability to continue operations last year.
In May this year, after reaching a licensing agreement with French pharmaceutical giant Sanofi (SNY.US), Novavax lifted its previously issued 'going concern' warning.
According to a statement released on Wednesday, Novavax will transfer a 0.15 million square foot recombinant protein manufacturing facility and ancillary buildings, existing workforce, and all related and necessary infrastructure to Novo Nordisk.
In addition to a cash payment of $0.19 billion in 2024 and an additional $10 million in 2025, Novavax expects that the sale of the facility will reduce annual operating costs by about $80 million.
Novavax President and CEO John C. Jacobs stated, 'The decision to sell the Czech manufacturing facility aligns with our previously announced commitment to transform Novavax into a more streamlined and agile organization focused on our pipeline assets and technology platform.'
The agreement is expected to be completed by December 30, 2024, at which point all responsibilities for the production facility will be transferred to novo-nordisk a/s.
As of the time of writing, novavax's pre-market stock is up 3.69%, while novo-nordisk a/s is down 0.64%.
